MELATONIN AND ITS EFFECT ON LEARNING AND MEMORY
MT2 receptors, again melatonin had no effect. However, in mice deficient only in MT1
receptors, melatonin did inhibit LTP. Thus, it is the MT2 receptors which allow
melatonin’s effect on LTP, and as long as the MT2 receptors are present, melatonin
works its effect in the hippocampus (Wang et al. 2005).
Dawn R. Collins suggested that perhaps the mechanism for melatonin’s inhibition
of LTP is based on N-methyl-D-aspartate (NMDA) receptors. Melatonin is similar in
structure to some NMDA receptor antagonists, and if melatonin blocks NMDA receptors,
then LTP would be inhibited. However, in experimentation, melatonin was found to have
no effect on NMDA receptor-mediated responses, thus not inhibiting LTP through a
mechanism involving the blockade on NMDA receptors (Collins and Davies 1997).
Wang hypothesized that the mechanism for LTP inhibition by melatonin involves
the inhibition of the Adenylyl cyclase- protein kinase A pathway (AC- PKA pathway),
which is involved in LTP. As MT2 receptors are negatively coupled to AC and PKA
activity, and melatonin is mediated through MT2 receptors, it seems possible that
melatonin’s mechanism of action is through the AC-PKA pathway. If it is true that
melatonin inhibits LTP through the inhibition of the AC-PKA pathway, then PKA
inhibitors should likewise inhibit LTP the same way that melatonin does. Therefore,
Wang tested H89, a PKA inhibitor, in its ability to inhibit the induction of LTP. H89 did
inhibit LTP, to the same extent as melatonin did. This experiment, as well as further
experiments testing the hypothesis, shows that melatonin works to block LTP induction
by a mechanism involving the inhibition of the AC-PKA pathway (Wang et al. 2005).
However, the mechanism for melatonin action in the hippocampus is not
straightforward. Takahashi demonstrated that melatonin blocked the induction of LTP
with a mechanism involving the inhibition of the nitric oxide (NO) signaling pathway.
The nitric oxide cascade is a precursor to LTP. In order for LTP to occur, a high-
frequency stimulation must be given, leading to postsynaptic calcium concentrations. The
calcium activates the production of nitric oxide. Nitric oxide leads to cGMP synthesis,
protein kinase G activation, and finally to LTP induction. Thus, by melatonin inhibiting
the nitric oxide signaling pathway, it leads to inhibition of LTP. One method Takahashi
used to prove this experimentally was the application of L-NAME, a nitric oxide synthase
inhibitor, to hippocampal slices. L-NAME inhibited LTP, just as melatonin did. Because
melatonin inhibits LTP by inhibiting nitric oxide pathway, both melatonin and nitric
oxide inhibitor should have the same end result of LTP inhibition. Each of them should
achieve the same LTP inhibition, and putting both melatonin and nitric oxide inhibitor
should not increase the level of LTP inhibition, because they both act on the same nitric
oxide pathway. Takahashi tried this and got the hypothesized results, supporting the idea
that melatonin inhibits LTP by inhibiting the nitric oxide cascade (Takahashi and Okada
2011).
Both the AC-PKA pathway and the nitric oxide pathway are mechanisms
involved in melatonin inhibition of LTP in the hippocampus. There is thought to be an
interaction between the two pathways (Takahashi and Okada 2011).
As previously mentioned, long-term potentiation is involved in learning and
memory. Everything discussed above about melatonin inhibiting LTP means that in some
way, melatonin is inhibiting the brain’s ability to learn and store memory. With the
endogenous melatonin produced naturally by the pineal gland, this inhibition is part of
the body’s natural cycle. Just as melatonin is produced in a circadian rhythm, LTP is also